FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. - Wikidata - awgldk - TriplyDB

FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.

FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.

http://www.wikidata.org/entity/Q37362737

about

Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.Metastatic gastric cancer treatment: Second line and beyond.A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer.Eastern Canadian Colorectal Cancer Consensus Conference 2017 Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers

P2860

Q35005019-53BE268E-756A-4264-B26C-984C976241FF Q36453663-707E1F81-616F-4F61-A455-5D91467FD598 Q38632917-B2782D0D-B625-49DB-84D1-D6145DC4232B Q42957434-81C3DA90-B70A-4E28-BFF7-2D546FDD3492 Q49645479-C8DE8AAF-291D-441D-BECC-5767B78AE262 Q49898050-5FB7B46A-02E9-4594-AEB4-89E47DDED4BD Q55155589-3FCAD527-C07E-42FF-ADDE-34E54B5405EC Q58783221-28C7E205-96FD-46D9-A7C8-545509A54B36 Q59138471-58481A47-43A7-45E7-AF23-E9053757AEDF

P2860

FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.

http://www.wikidata.org/entity/Q37362737

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

FOLFIRI as a second-line thera ...... c cancer: a historical cohort.

@en

FOLFIRI as a second-line thera ...... c cancer: a historical cohort.

@nl

type

label

FOLFIRI as a second-line thera ...... c cancer: a historical cohort.

@en

FOLFIRI as a second-line thera ...... c cancer: a historical cohort.

@nl

prefLabel

FOLFIRI as a second-line thera ...... c cancer: a historical cohort.

@en

FOLFIRI as a second-line thera ...... c cancer: a historical cohort.

@nl

P1433

Q37362737-65F5A25E-F1DA-44A3-9A3D-4408BACCEB6A

P1476

Q37362737-25D4E7BF-DAA9-4F81-AF76-530A2C76E548

P2093

Q37362737-01809D26-190A-4E9F-9F74-9D73BC002C29

Q37362737-0362AC4D-48AF-4142-8BA7-88305E443381

Q37362737-372341EC-CCF2-4952-A1F3-FADDB2C955B4

Q37362737-74D9FF53-750C-4B83-9BF5-D212EFACAAE6

Q37362737-C87CB7B5-2193-45CC-87A6-6B73BA78A92C

Q37362737-FDD0B006-FD10-4078-9A2F-72EACB6BB6B4

P2860

Q37362737-01E25DDF-91A8-45D8-997E-6A2B9A6F4338

Q37362737-047A6148-625F-456E-B2AB-86023C316DD1

Q37362737-272F4B8C-8DA4-4FAE-A9A2-C1B74364DA1E

Q37362737-3638C19A-6AB1-45FC-8153-5F83F952BDB2

Q37362737-4001E836-F0F0-43E9-B249-DADEA22CFEE0

Q37362737-44FA26D7-48D6-4F70-81C3-25D2A257660F

Q37362737-4CC3CA20-6BDB-46B0-BD61-BD2C613F9AB0

Q37362737-65561EAF-4E1A-4A1F-921D-0B53AD711BCE

Q37362737-76E2577A-2FC1-4985-9B24-54CE9B3B285F

Q37362737-796D9BD3-C3A0-4D82-B57B-3D5FCEC3EC3F

P2888

Q37362737-E20E2F1E-105A-49AC-A769-3D830317FBF7

P304

Q37362737-8BB0AABA-25B1-4FBA-97A0-E75A2A109F9D

P31

Q37362737-E160A651-9706-4DAF-8E64-2466653707CB

P356

Q37362737-97154ADD-8322-44C9-BC7B-7AF50A349322

P478

Q37362737-661E512C-DE97-4C7B-8295-B3CD3C48E9F1

P50

Q37362737-4B6025A6-7E28-4E02-BBFA-A1CDCDD7B50B

Q37362737-62F5B473-AFC9-43BA-B9CE-EFB304BFB8A2

Q37362737-63146E0C-D545-457D-8B6C-2E32751317C4

Q37362737-68B691E3-9FD0-4729-9585-B3EA4E1AD19F

Q37362737-C7DC9762-0830-4204-9AB9-2DAF6DA47643

P577

Q37362737-CAEA8C60-3DC2-4D98-BFB5-5D0F1E07C47D

P5875

Q37362737-0086CC54-D5E2-4891-8806-6819879BF12C

P6179

Q37362737-41873FB4-E7F8-41F6-8ACF-AB7422FFA2A4

P698

Q37362737-5D036A4D-AB1C-4F32-AAB5-A68A24B4DE43

P932

Q37362737-6753F347-77B3-498E-8DE8-72E900DC63EA

P356

1756-9966-32-67

P1433

Journal of Experimental & Clinical Cancer Research

P1476

FOLFIRI as a second-line thera ...... ic cancer: a historical cohort

@en

P2093

Antonella Amodio

http://www.w3.org/2001/XMLSchema#string

Franca Belli

http://www.w3.org/2001/XMLSchema#string

Laura Pizzuti

http://www.w3.org/2001/XMLSchema#string

Luigi Di Lauro

http://www.w3.org/2001/XMLSchema#string

Sara Boggia

http://www.w3.org/2001/XMLSchema#string

Silvia Fattoruso

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

A microRNA expression signature of human solid tumors defines cancer gene targets

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis.

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

P2888

1756-9966-32-67

P304

67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-9966-32-67

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Maddalena Barba

Diana Giannarelli

M Maugeri-Saccà

P577

2013-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259315872

http://www.w3.org/2001/XMLSchema#string

P6179

1041327328

http://www.w3.org/2001/XMLSchema#string

P698

24330513

http://www.w3.org/2001/XMLSchema#string

P932

3850248

http://www.w3.org/2001/XMLSchema#string